このエントリーをはてなブックマークに追加
ID 54507
JaLCDOI
フルテキストURL
Thumnail 70_4_295.pdf 1.83 MB
著者
Araki, Motoo Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Wada, Koichiro Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Mitsui, Yosuke Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kubota, Risa Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Yoshioka, Takashi Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Ariyoshi, Yuichi Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kobayashi, Yasuyuki Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kitagawa, Masashi Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Tanabe, Katsuyuki Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Sugiyama, Hiroshi Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Wada, Jun Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Watanabe, Masami Center for Innovative Clinical Medicine, Okayama University Hospital
Watanabe, Toyohiko Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Hotta, Katsuyuki Center for Innovative Clinical Medicine, Okayama University Hospital
Nasu, Yasutomo Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
抄録
Although graft survival following renal transplantation (RTx) has improved, outcomes following highrisk RTx are variable. Preexisting antibodies, including donor-specific antibodies (DSA), play an important role in graft dysfunction and survival. We have designed a study to investigate the safety and efficacy of anti-CD20 monoclonal antibodies (rituximab) in high-risk RTx recipients. Major eligibility criteria include: 1) major and minor ABO blood group mismatch, 2) positive DSA. Thirty-five patients will receive 200 mg/body of rituximab. The primary endpoint is the incidence of B cell depletion. This study will clarify whether rituximab is efficacious in improving graft survival in high-risk RTx recipients.
キーワード
end-stage renal disease
immunosuppression
kidney transplantation
Amo Type
Clinical Study Protocols
発行日
2016-08
出版物タイトル
Acta Medica Okayama
70巻
4号
出版者
Okayama University Medical School
開始ページ
295
終了ページ
297
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
English
著作権者
CopyrightⒸ 2016 by Okayama University Medical School
論文のバージョン
publisher
査読
有り
PubMed ID
Web of Sience KeyUT